Rho Ventures V L.P. 13D and 13G filings for NGM Biopharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-13 12:57 pm Sale |
2022-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM |
Rho Ventures V L.P. | 430,783 0.500% |
-3,372,487 (-88.67%) |
Filing |
| 2021-02-16 2:53 pm Purchase |
2020-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM |
Rho Ventures V L.P. | 3,803,270 5.500% |
12,604 (+0.33%) |
Filing |
| 2021-02-12 5:25 pm Purchase |
2020-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM |
Rho Ventures V L.P. | 3,790,666 5.500% |
6,000 (+0.16%) |
Filing |